LY 541850 |
Catalog No.GC36504 |
LY 541850 est revendiqué À partir de récepteurs humains ionotropes et métabotropes du glutamate (mGlu) exprimés dans des cellules non neuronales.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 852679-76-6
Sample solution is provided at 25 µL, 10mM.
LY 541850 is claimed from human ionotropic and metabotropic glutamate (mGlu) receptors expressed in non-neuronal cells. LY541850 is a selective orthosteric mGlu2 agonist and mGlu3 antagonist with IC50 values of 0.161 μM and 0.038 μM, respectively[1]. mGluR2|0.161 μM (IC50)|mGluR3|1.05 μM (IC50)
LY 541850 (intraperitoneal injection; 10 mg/kg-300 mg/kg; 15 min prior) induces a concentration-dependent inhibition of the TAP evoked fEPSPs in CA1-SLM in 10-16 week old (EC50 42 nM) in CD-1 mice[1]. LY 541850 (intraperitoneal injection; 10 mg/kg-300 mg/kg; 30 min prior) reduces the increased locomotor activity of phencyclidine and amphetamine in a dose-dependent manner in male ICR mice[1].
[1]. Hanna L, et al. Differentiating the roles of mGlu2 and mGlu3 receptors using LY541850, an mGlu2 agonist/mGlu3 antagonist. Neuropharmacology. 2013 Mar;66:114-21.
Average Rating: 5
(Based on Reviews and 28 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *